1-2 of 2
Louai Labanieh
Close
Sort by
Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Robbie G. Majzner, MD, Matthew J. Frank, MD PhD, Christopher Mount, MD PhD, Aidan Tousley, David M. Kurtz, MDPhD, Brian Sworder, MD PhD, Katherine A Murphy, Antigoni Manousopoulou, Kennedy Kohler, Maria Caterina Rotiroti, PhD, Jay Y. Spiegel, MDFRCPC, Yasodha Natkunam, MD PhD, Sheren F. Younes, MD PhD, Elena Sotillo, PhD, Vandon Duong, Charles Macaulay, MSc, BA, Zinaida Good, PhD, Peng Xu, MD, Louai Labanieh, Leo D Wang, MD PhD, Ash A. Alizadeh, MD PhD, Michelle Monje, MD PhD, David B. Miklos, MD PhD, Crystal L. Mackall, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-139605
Published: 2020
Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 963.
https://doi.org/10.1182/blood-2018-99-115558
Published: 2018